- Trials with a EudraCT protocol (1,844)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,844 result(s) found for: Brain diseases.
Displaying page 1 of 93.
EudraCT Number: 2011-003618-18 | Sponsor Protocol Number: M10-897 | Start Date*: 2013-04-19 | |||||||||||
Sponsor Name:Abbott GmbH & Co. KG | |||||||||||||
Full Title: A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Su... | |||||||||||||
Medical condition: Brain metastases from NSCLC | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) BE (Completed) CZ (Completed) FI (Completed) ES (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005669-54 | Sponsor Protocol Number: UKM2013-0034 | Start Date*: 2020-06-02 | |||||||||||
Sponsor Name:Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Personal und Recht | |||||||||||||
Full Title: Clinical safety study on 5-Aminolevulinic acid (5-ALA) in children and adolescents with brain tumours | |||||||||||||
Medical condition: intra-axial brain tumor (malignant glioma, astrocytoma, malignant ependymoma, AT/RT, Oligodendroglioma, etc.) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001879-20 | Sponsor Protocol Number: 38RC18.085 | Start Date*: 2018-07-30 | |||||||||||
Sponsor Name:Grenoble Alps University Hospital | |||||||||||||
Full Title: Radiotherapy of multiple brain metastases using AGuIX® gadolinium-chelated polysiloxane based nanoparticles: a prospective randomized phase II clinical trial. | |||||||||||||
Medical condition: Patients with brain metastases, from a histologically confirmed solid tumor, eligible for WBRT | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003227-35 | Sponsor Protocol Number: 755/11 | Start Date*: 2011-10-04 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: 18F-FECh-PET in patients with brain tumors | |||||||||||||
Medical condition: brain tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005194-32 | Sponsor Protocol Number: CRANIAL | Start Date*: 2013-06-28 | ||||||||||||||||
Sponsor Name:Institut Jules Bordet | ||||||||||||||||||
Full Title: A phase II trial evaluating Cabazitaxel in patients with brain metastasis secondary to breast and non-small-cell lung cancer | ||||||||||||||||||
Medical condition: Brain metastasis secondary to HER2-negative breast cancer and NSCLC, not previously irradiated and not requiring immediate radiation. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-000661-12 | Sponsor Protocol Number: OCTO_022 | Start Date*: 2011-08-23 | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: A randomised double blind phase 2 trial of whole brain radiotherapy with or without vandetanib in metastatic melanoma with brain metastases | |||||||||||||
Medical condition: Metastatic melanoma with brain metastases. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006694-39 | Sponsor Protocol Number: ASF-CP02-001 | Start Date*: 2022-07-08 | ||||||||||||||||
Sponsor Name:Lantmännen Medical AB | ||||||||||||||||||
Full Title: An open-label, historical cohort control study to evaluate the safety and tolerability of AF-16 in patients with cerebral oedema caused by traumatic brain injury (TBI) | ||||||||||||||||||
Medical condition: Cerebral oedema caused by traumatic brain injury (TBI) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003391-40 | Sponsor Protocol Number: 2020-KEP-456 | Start Date*: 2020-12-17 | |||||||||||
Sponsor Name:London School of Hygiene and Tropical Medicine | |||||||||||||
Full Title: Intramuscular tranexamic acid for the treatment of symptomatic mild traumatic brain injury in older adults: a randomised, double-blind, placebo-controlled trial. | |||||||||||||
Medical condition: Mild traumatic brain injury. | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004512-58 | Sponsor Protocol Number: INV-GEM-0200-I | Start Date*: 2020-08-17 | |||||||||||
Sponsor Name:Technische Universität München, Fakultät für Medizin | |||||||||||||
Full Title: Comparison of Fluorescein-INtra-VItal microscopy Versus conventional frozen section diagnosis for intraOperative histopathological evaluation | |||||||||||||
Medical condition: Intracranial tumor | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006301-10 | Sponsor Protocol Number: MAGNA | Start Date*: 2012-05-10 | ||||||||||||||||
Sponsor Name:Fundació Clinic per a la Recerca Biomèdica | ||||||||||||||||||
Full Title: Perioperative Magnesium Sulphate as a cerebral protector in neurosurgical patients | ||||||||||||||||||
Medical condition: Patient who are going to be under cerebral parenchyma resection, due to epilepsy or tumor | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003669-14 | Sponsor Protocol Number: ISRCTN15088122 | Start Date*: 2012-12-03 | |||||||||||
Sponsor Name:London School Of Hygiene and Tropical Medicine | |||||||||||||
Full Title: Tranexamic Acid for the treatment of significant traumatic brain injury: an international, randomised, double blind, placebo controlled trial. | |||||||||||||
Medical condition: Traumatic Brain Injury | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) GB (Completed) IT (Completed) IE (Completed) SI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003382-38 | Sponsor Protocol Number: FSNANO05012022 | Start Date*: 2023-01-12 | |||||||||||
Sponsor Name:FSNANO05012022 | |||||||||||||
Full Title: Efficacy and safety of Cerebrolysin for neurorecovery after moderate-severe traumatic brain injury | |||||||||||||
Medical condition: Moderate-severe traumatic brain injury | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003804-15 | Sponsor Protocol Number: SGMCBM | Start Date*: 2023-12-19 | ||||||||||||||||
Sponsor Name:Leiden University Medical Center | ||||||||||||||||||
Full Title: A FEASIBILITY STUDY OF SGM-101, A FLUOROCHROME-LABELED ANTI-CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY FOR THE INTRAOPERATIVE DETECTION OF COLORECTAL BRAIN METASTASES | ||||||||||||||||||
Medical condition: Colorectal brain metastases | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004974-16 | Sponsor Protocol Number: IL1ra03 | Start Date*: 2018-11-08 | ||||||||||||||||
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge | ||||||||||||||||||
Full Title: DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMISED CLINICAL DOSE-RANGING STUDY TREATING MODERATE-SEVERE TRAUMATIC BRAIN INJURY PATIENTS WITH RECOMBINANT HUMAN INTERLEUKIN 1 RECEPTOR ANTAGONIST. | ||||||||||||||||||
Medical condition: We wish to study the drug Kineret in patients suffering from moderate-to-severe traumatic brain injury | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-004596-31 | Sponsor Protocol Number: NL62772 | Start Date*: 2019-03-25 | ||||||||||||||||
Sponsor Name:UMC Utrecht | ||||||||||||||||||
Full Title: CeRebrUm and CardIac protection with Allopurinol in neonates with critical congenital heart disease requiring cardiac surgery with cardiopulmonary bypass | ||||||||||||||||||
Medical condition: Brain injury in neonates with critical congenital heart disease requiring cardiac surgery with cardiopulmonary bypass. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Newborns, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002328-24 | Sponsor Protocol Number: BRAIN | Start Date*: 2015-09-04 |
Sponsor Name:UZ Brussel | ||
Full Title: Evaluation of 68GaNOTA-Anti-HER2 VHH1 uptake in brain metastasis of cancer patients | ||
Medical condition: brain metastasis lesions from potential HER2 cancer patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003994-80 | Sponsor Protocol Number: ET18-270 | Start Date*: 2019-10-03 | |||||||||||
Sponsor Name:Centre Léon Bérard | |||||||||||||
Full Title: A Phase II study evaluating AGuIX® nanoparticles in combination with Stereotactic Radiation for oligo brain metastases | |||||||||||||
Medical condition: Brain metastases | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018283-16 | Sponsor Protocol Number: BHR-100-301 | Start Date*: 2010-09-24 | |||||||||||
Sponsor Name:BHR Pharma, LLC | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Investigate the Efficacy and Safety of Progesterone in Patients with Severe Traumatic Brain Injury | |||||||||||||
Medical condition: Severe traumatic brain injury | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) HU (Completed) GB (Completed) CZ (Completed) NL (Completed) AT (Completed) DE (Completed) ES (Completed) IT (Completed) FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000140-58 | Sponsor Protocol Number: NL7255100000 | Start Date*: 2020-07-23 | |||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||
Full Title: Complement Inhibition: Attacking the Overshooting Inflammation @fter Traumatic Brain Injury - A phase II trial on the safety and efficacy of C1 esterase inhibitor Cinryze for the acute management o... | |||||||||||||
Medical condition: Severe traumatic Brain Injury (TBI) with GCS < 13 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002714-11 | Sponsor Protocol Number: EORTC 22033-26033 | Start Date*: 2005-06-06 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer | |||||||||||||
Full Title: Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study | |||||||||||||
Medical condition: Histologically proven low-grade glioma ♦ Astrocytoma WHO grade II (gemistocytic, fibrillary and protoplasmatic) ♦ Oligoastrocytoma WHO grade II ♦ Oligodendroglioma WHO grade II | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DE (Completed) GB (Completed) IT (Completed) DK (Prematurely Ended) BE (Completed) ES (Completed) PT (Completed) HU (Completed) SE (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
